KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Total Debt (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Total Debt readings, the most recent being $38.5 million for Q4 2025.

  • On a quarterly basis, Total Debt fell 88.94% to $38.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.5 million, a 88.94% decrease, with the full-year FY2025 number at $38.5 million, down 88.94% from a year prior.
  • Total Debt hit $38.5 million in Q4 2025 for Biocryst Pharmaceuticals, down from $232.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $349.7 million in Q1 2025 to a low of $38.5 million in Q4 2025.
  • Median Total Debt over the past 5 years was $232.3 million (2023), compared with a mean of $234.0 million.
  • Biggest five-year swings in Total Debt: surged 186.81% in 2021 and later plummeted 88.94% in 2025.
  • Biocryst Pharmaceuticals' Total Debt stood at $136.1 million in 2021, then soared by 70.21% to $231.6 million in 2022, then skyrocketed by 41.09% to $326.8 million in 2023, then increased by 6.35% to $347.5 million in 2024, then plummeted by 88.94% to $38.5 million in 2025.
  • The last three reported values for Total Debt were $38.5 million (Q4 2025), $232.1 million (Q3 2025), and $278.5 million (Q2 2025) per Business Quant data.